Current clinical trials

The BSH is keen to support research related to heart failure in the UK. 

Please feel free to contact the clinical trial investigator if you are interested in taking part.

If you are running a clinical trial in the UK and would like to advertise the details here, please contact us.

Trial: ISCOMAT (Improving the Safety and Continuity Of Medicines At Care Transitions)

Details: ISCOMAT is an NIHR-funded  5-year programme to improve how medicines are managed for people with heart failure across the care transition from hospital to home. It is a collaboration between the Universities of Bradford and Leeds and Bradford Teaching Hospitals NHS Foundation Trust.

Along with an analysis of the whole pathway for heart failure patients, ISCOMAT has worked with patients and staff to co-design an intervention to help improve patient outcomes. Following a successful feasibility study, we are preparing for a Randomised Cluster Control trial, beginning in Spring 2018. We are currently welcoming returns of our Site Feasibility Questionnaire from hospital sites interested in taking part in the trial.

Contact: To request a copy of this, please email: To find out more about the study, see our web pages at

Trial: SUPPORT HF-2 (Seamless User-centred Proactive Provision Of Risk-stratified Treatment for Heart Failure)

Details: A study of home monitoring for the management of heart failure with integrated data analysis and risk stratification tools providing alerts to patients and health care practitioners. More information. 
See the trial website. Interest from new sites is welcome. Please get in touch with the Trial Manager if you are interested in participating or would like more information

Investigator: Professor Kazem Rahimi, The George Institute for Global Health, University of Oxford (

Trial Manager: Denise Fleming-Brown, The George Institute for Global Health, University of Oxford (

Trial: IRON-MAN - Intravenous iron treatment in patients with heart failure and iron deficiency

BHF funded

Study population - patients with iron deficiency and heart failure due to left ventricular systolic dysfunction. PROBE (prospective, randomised, open-label blinded end point) design with primary endpoint CV mortality and hospitalisation for worsening heart failure, aiming to recruit 1300 patients.

Status: 660 patients recruited from 67 centres (January 2019) 

Key study to answer very important clinical question. In addition, crucial to complete timely recruitment to demonstrate to funders that the UK can deliver large, multi-centre HF studies. Please contact CI if you are interested in opening as a site. If site already open please try to increase recruitment (ideally at least one patients per site per month).

Contact: Paul Kalra (

Trial: Simulated case management of home telemonitoring to assess the impact of different alert algorithms on work-load and clinical decisions

Details: The University of Hull are looking for heart failure nurses/doctors with experience of managing patients with heart failure using home telemonitoring systems to participate in a case-load simulation study. We are looking to better understand the effect of home telemonitoring alerts on the decision making of healthcare professionals in the management of patients with heart failure. If you are interested in participating please complete our short survey at

Investigator: Kevin Goode (


Details: study of vagal stimulation in patients with severe heart failure in addition to best medical therapy. An implantable device delivers electrical stimulation to the vagus nerve in the neck. No new centres required however trialists keen to develop referral networks

Investigator: Rami Biran (

Trial: REVIVED-BCIS2 (REVascularisation for Ischaemic VEntricular Dysfunction)

Details: This randomised controlled trial is designed to evaluate whether percutaneous coronary intervention (in combination with Optimal Medical Therapy [OMT]) can improve event free survival in patients with sever ischaemic cardiomyopathy, compared to treatment with OMT alone. Patients with poor left ventricular function (EF<35%) and extensive coronary artery disease will be eligible for inclusion, provided they have evidence of viable myocardium. The primary endpoint is all cause death or hospitalisation due to heart failure. Patients will be followed up for at least 2 years (range 2-5 years). The trial is sponsored by King's College London, funded by the National Institute for Health Research HTA and overseen by an independent Trial Steering Committee.

REVIVED represents a unique collaboration between heart failure and interventional cardiology, a feature that will be central to successful delivery of the trial and also serve as a model for how these patients may be managed in the future. There will be heart failure and intervention leads at each participating centre, while the study group includes past and current presidents of BCIS and chairs of BSH.

More details: see the trial website. Interest from new sites is welcome. Please get in touch with the Trial Manager if you are interested in participating or would like more information.

Chief Investigator: Divaka Perera, St Thomas' Hospital Campus, KCL (

Trial Manager: Richard Evans, Clinical Trials Unit, LSHTM (